BMS/Pfizer set for European Eliquis launch after VTE prevention approval
This article was originally published in Scrip
Executive Summary
Bristol-Myers Squibb and Pfizer are set for European launches of their oral direct Factor Xa inhibitor, Eliquis (apixaban), after receiving approval from the European Commission for its use in the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery.